文献速递艾滋病与性传播感染

拉米夫定联合拉替拉韦或多替拉韦简化双药方案在HIV病毒学抑制患者中的疗效与耐受性

Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

本研究为观察性回顾性研究,纳入109例病毒学抑制的HIV感染者,切换至拉米夫定300mg每日一次联合拉替拉韦1200mg每日一次或多替拉韦50mg每日一次的双药维持方案。12个月时两组HIV RNA<20 copies/mL的比例分别为90%和88.1%,疗效高且相当,耐受性良好,但多替拉韦组头痛和睡眠障碍发生率更高。

要点

  • 拉米夫定联合拉替拉韦或多替拉韦双药简化方案在病毒学抑制患者中12个月病毒学抑制率约90%。
  • 两组严重不良事件均未发生,多替拉韦组头痛和睡眠障碍发生率显著高于拉替拉韦组。
  • 两组体重增加程度相当且无统计学意义。

核心结论

  • 拉米夫定联合拉替拉韦或多替拉韦的双药维持方案在病毒学抑制的HIV感染者中显示出高且相当的疗效和良好的耐受性。

研究设计与样本

  • 观察性回顾性研究,纳入109例病毒学抑制的HIV感染患者,其中50例切换至拉米夫定加拉替拉韦(A组),59例切换至拉米夫定加多替拉韦(B组)。

主要发现

  • 12个月时A组45例(90%)和B组52例(88.1%)患者HIV RNA<20 copies/mL。
  • 两组均无严重不良事件,B组头痛和睡眠障碍发生率高于A组(30.5% vs 14%,P<0.001)。
  • 两组体重增加相当且无统计学意义(A组+1.91 kg,B组+2.28 kg)。

临床怎么用

  • 对于病毒学抑制的HIV感染者,可考虑拉米夫定联合拉替拉韦或多替拉韦的双药简化方案以优化联合抗逆转录病毒治疗、预防长期毒性并降低治疗成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiretroviral dual regimens including lamivudine and one boosted PI or dolutegravir are warranted in order to optimize combination ART (cART), prevent long-term toxicity and reduce the cost of treatments. OBJECTIVES: We hypothesized that a maintenance dual regimen of lamivudine plus raltegravir would be effective and as well tolerated as the dual maintenance combination of lamivudine plus dolutegravir. METHODS: We performed an observational, retrospective study of HIV-infected patients on suppressive ART who switched to a dual regimen containing lamivudine 300 mg once daily plus raltegravir 1200 mg once daily or dolutegravir 50 mg once daily. RESULTS: In total, 109 patients (79 men; mean age 46.4 years; mean CD4+ T lymphocyte count 605 cells/mm3) were enrolled. Overall, 50 subjects switched to lamivudine plus raltegravir (Group A) and 59 to lamivudine plus dolutegravir (Group B). After 12 months, 45 patients (90%) in Group A and 52 (88.1%) in Group B had HIV RNA <20 copies/mL. No patients had severe adverse effects in either group, and the percentages of patients with mild adverse effects were comparable, except for a higher incidence of headache and sleeping disturbances in Group B than in Group A (30.5% versus 14%, P < 0.001). A comparable and non-significant weight increase was reported in both groups (+1.91 kg in Group A and +2.28 kg in Group B). CONCLUSIONS: In our study, dual therapies containing lamivudine plus raltegravir or dolutegravir in virologically suppressed patients showed high and comparable efficacy, as well as good tolerability.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Calza L, Colangeli V, Borderi M, et al. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. J Antimicrob Chemother. 2020. PMID: 32728708. doi:10.1093/jac/dkaa319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。